National Viral Hepatitis Action Plan

Local Health Departments and Hepatitis C: Webcast 1.2

Presented by:
Corinna Dan, RN, MPH
Office of HIV/AIDS and Infectious Disease Policy
Department of Health and Human Services
Overview

- Impact
- Response
- Importance of Stakeholders
- Local Health Department Roles
Impact
### 2013 Viral Hepatitis Epidemiology, U.S.

<table>
<thead>
<tr>
<th></th>
<th>Hepatitis A (HAV)</th>
<th>Hepatitis B (HBV)</th>
<th>Hepatitis C (HCV)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute cases</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(annual estimated)</td>
<td>3,473</td>
<td>19,764</td>
<td>29,718</td>
</tr>
<tr>
<td></td>
<td>14%↑ in reported</td>
<td>5.4%↑ in reported</td>
<td>151.5%↑ in</td>
</tr>
<tr>
<td></td>
<td>cases compared to</td>
<td>cases compared to</td>
<td>reported cases</td>
</tr>
<tr>
<td></td>
<td>2012</td>
<td>2012</td>
<td>from 2010 to 2013</td>
</tr>
<tr>
<td><strong>Chronic infections</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(prevalent cases)</td>
<td></td>
<td>700,000 – 1.4</td>
<td>2.7-3.9 million</td>
</tr>
<tr>
<td></td>
<td></td>
<td>million</td>
<td></td>
</tr>
<tr>
<td><strong>Est. perinatal</strong></td>
<td></td>
<td>800 – 1,000</td>
<td>?</td>
</tr>
<tr>
<td>(annual estimated)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Deaths (2013)</strong></td>
<td>80</td>
<td>1,873</td>
<td>19,368</td>
</tr>
<tr>
<td>(annual reported)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Between 45% to 65% of chronically infected persons are unaware of their infection status.*

The Evolution of Our National Response
Viral Hepatitis Action Plan (Updated 2014-2016)

6 Priority Areas

- Educating providers and communities
- Improving testing, care, and treatment
- Strengthening surveillance
- Eliminating transmission of vaccine-preventable viral hepatitis
- Reducing viral hepatitis cases associated with drug-use behaviors
- Protecting patients and workers from health-care-associated viral hepatitis
Proposed 2020 Goals of the Viral Hepatitis Action Plan (full implementation)

- Increase the proportion of persons who are aware of their HBV infection from 33% to 66%
- Increase the proportion of persons who are aware of their HCV infection from 45% to 66%
- Reduce the number of new HCV infections by 25%
- Eliminate mother-to-child HBV transmission
Affordable Care Act Opportunities

- Elimination of pre-existing condition restrictions
- Expanded access to health insurance
- Preventive health care coverage
  - Screening
    - USPSTF Grade A or B
  - Vaccination
    - ACIP recommended
HCV Therapy Has Undergone a Revolution

FDA approves first combination pill to treat hepatitis C

For Immediate Release
October 10, 2014

The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.

Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.
Gaps in the U.S. HCV Continuum of Care

Yehia et al, PLOS One, 2014

www.aids.gov/hepatitis • #ViralHepAction
Importance of Stakeholders
U.S. Viral Hepatitis Action Plan and Stakeholders’ Workbook

Activity Plan for the Prevention, Care, & Treatment of Viral Hepatitis

Updated
2014-2016

STAKEHOLDERS' WORKBOOK
Exploring Vital Roles and Opportunities to Break the Silence

CONTINUING TO COMBAT THE SILENT EPIDEMIC OF VIRAL HEPATITIS
Action Plan for the Prevention, Care, & Treatment of Viral Hepatitis
Updated 2014-2016

Developed by the Office of HIV/AIDS and Infectious Disease Policy for planning purposes only

Visit http://aids.gov/hepatitis
The Vital Role of Stakeholders

The updated VHAP underscores that its national goals cannot be achieved through federal action alone.

Active involvement, and innovation, from a broad mix of nonfederal stakeholders from various sectors, both public and private, is essential.

The VHAP provides a framework and focus around which all stakeholders can engage to strengthen the nation’s response to viral hepatitis.
Stakeholders’ Workbook

Purpose:
Facilitate opportunities to talk through potential activities, challenges, tools, resources, and partnerships related to each priority area.

- Discussion questions provided, e.g.:
  - What are the best ways to identify persons with chronic viral hepatitis who do not know they are infected? What can your organization do to promote this?

- Sample hepatitis planning sheet to prioritize, set timeframes, & measures
Health Department Roles
Examples of Opportunities for Health Departments:

- Help disseminate professional training tools and materials.
- Use CDC’s hepatitis campaign materials to help spread the word about the importance of getting tested for viral hepatitis.
- Hold regular hepatitis testing events, and participate in National Testing Day on May 19th.
- Continue to build coalitions to expand the ability to reach populations most impacted by viral hepatitis.
- Support surveillance projects and epidemiological investigations to help understand the characteristics and needs of the emerging hepatitis C epidemic among people who inject drugs.
- Develop more detailed information about population-specific health disparities in viral hepatitis prevention, diagnosis, care, and treatment.
Know More Hepatitis

Materials available at www.cdc.gov/hepatitis

Courtesy of CDC DVH Education, Training, & Communications Team

www.aids.gov/hepatitis • #ViralHepAction
We Have the Tools!

▲ Centers for Disease Control and Prevention
   ▪ Educational materials, training resources, and guidelines
   ▪ www.cdc.gov/hepatitis

▲ U.S. Department of Health and Human Services
   ▪ Viral Hepatitis Action Plan, Stakeholders’ Workbook, updates & reports, and blogs
   ▪ www.AIDS.gov/hepatitis

▲ Veterans Administration
   ▪ Patient and Provider education and tools
   ▪ http://www.hepatitis.va.gov/

▲ American Association for the Study of Liver Disease
   ▪ Primary healthcare provider training on viral hepatitis
   ▪ http://www.aasld.org/act-first-free-online-cme-course-primary-care-providers
Be the Action in the Viral Hepatitis Action Plan!

Thank you!

Corinna Dan, RN, MPH
Corinna.Dan@hhs.gov
Local Health Departments and Hepatitis C
NACCHO Educational Series

Webcast 1.1  Hepatitis C: Where Are We Now?
Webcast 1.2  The National Viral Hepatitis Action Plan
Webcast 1.3  Viral Hepatitis C Testing Recommendations for Persons Born 1945-1965
Webcast 1.4  Leveraging Partnerships to Address Hepatitis C: Philadelphia’s Model

All materials available at www.naccho.org/hepatitisc

NACCHO’s educational series is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP and funding from Gilead Sciences, Inc.